Armata Pharmaceuticals, Inc. — Form 8-K
Filed July 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Armata received FDA agreement on an Agreed Initial Pediatric Study Plan (iPSP) for AP-SA02, establishing a regulatory framework for pediatric evaluation in complicated Staphylococcus aureus bacteremia patients up to age 17. Pediatric studies will be deferred until adult Phase 3 data are generated (Phase 3 expected to start H2 2026), followed by a single open-label pediatric safety/efficacy study. No financial figures, counterparties beyond FDA, or share counts disclosed.
Why this rating
Regulatory milestone de-risks clinical path for lead candidate; expands addressable market to pediatrics. Material for $21M company but contingent on Phase 3 success.
See more from July 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.